Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a rare but serious condition characterized by high blood pressure in the arteries of the lungs, leading to symptoms such as shortness of breath, fatigue, and chest pain.
Pulmonary Arterial Hypertension: LTP001 Treatment Study
We are studying a new treatment called LTP001 in healthy adults and in individuals with pulmonary arterial hypertension. The goal is to evaluate its safety and how well it may improve exercise capacity and overall health.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have pulmonary arterial hypertension (high blood pressure in the lungs)?
- Are you currently taking stable doses of standard treatments for pulmonary arterial hypertension?
- Are you a male or a female who cannot become pregnant?
- Have you had any serious heart problems or surgeries that could affect your safety in this study?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Ltp001
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
Department of Pneumology
Heverlee, Belgium
Hopital Erasme
Department of Cardiology
Negenmanneke, Belgium
Institute For Clinical And Experimental Medicine
Klinika kardiologie Ambulance plicní hypertenze
Prague, Czechia
Sponsor: Novartis Pharma AG
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.